Samsung BioLogics Co., the contract drug manufacturing unit of South Korean conglomerate Samsung Group, is planning to raise as much as $2.5 billion from an initial public offering that would value it at roughly $10 billion, according to people familiar with the matter.
The company, which manufactures complex biologic drugs on behalf of clients like Bristol-Myers Squibb Co. and Roche Holding, expects to file this week for approval to list shares in South Korea, one of the people said. It expects to complete the share offering in the fourth quarter of this year, the person said.
